BridgeBio Pharma Quarterly Income Statements Chart
Quarterly
|
Annual
BridgeBio Pharma Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues: | |||||||||||||||||||||||||
| license and services revenue | 37,440,000 | 79,894,000 | 1,826,000 | 1,775,000 | 338,000 | 73,746,000 | |||||||||||||||||||
| net product revenue | 71,501,000 | 36,739,000 | |||||||||||||||||||||||
| royalty revenue | 1,624,000 | ||||||||||||||||||||||||
| total revenues | 110,565,000 | 116,633,000 | |||||||||||||||||||||||
| operating costs and expenses: | |||||||||||||||||||||||||
| cost of revenues: | |||||||||||||||||||||||||
| cost of license, services and royalty revenue | 805,000 | ||||||||||||||||||||||||
| cost of goods sold | 2,848,000 | 2,034,000 | |||||||||||||||||||||||
| total cost of revenues | 3,653,000 | 2,639,000 | |||||||||||||||||||||||
| research and development | 111,231,000 | 111,431,000 | 130,350,000 | 120,444,000 | 114,695,000 | 140,972,000 | 130,226,000 | 125,136,000 | 107,488,000 | 92,861,000 | 90,902,000 | 92,511,000 | 108,400,000 | 107,649,000 | 122,200,000 | 104,305,000 | 101,960,000 | 122,559,000 | 90,174,000 | 92,050,000 | 86,598,000 | 68,225,000 | 57,485,000 | 55,278,000 | 52,331,000 |
| selling, general and administrative | 129,154,000 | 106,365,000 | 94,782,000 | 68,819,000 | 59,523,000 | 65,807,000 | 47,583,000 | 35,777,000 | 36,122,000 | 31,108,000 | 31,862,000 | 31,188,000 | 36,426,000 | 43,713,000 | 54,749,000 | 46,084,000 | 45,970,000 | ||||||||
| restructuring, impairment and related charges | 805,000 | 570,000 | 4,693,000 | 4,621,000 | 2,891,000 | 3,400,000 | 754,000 | 272,000 | 3,531,000 | 3,369,000 | 7,691,000 | 5,016,000 | 8,396,000 | 22,662,000 | |||||||||||
| total operating costs and expenses | 244,843,000 | 221,005,000 | 231,909,000 | 194,482,000 | 177,707,000 | 210,777,000 | 179,161,000 | 161,783,000 | 147,740,000 | 127,989,000 | 131,102,000 | 129,454,000 | 153,922,000 | 175,372,000 | 178,500,000 | 151,843,000 | 148,039,000 | ||||||||
| income from operations | -134,278,000 | -104,372,000 | -226,027,000 | -191,750,000 | -175,539,000 | 343,000 | -177,416,000 | -157,692,000 | -146,099,000 | -126,163,000 | -129,232,000 | -129,116,000 | -80,176,000 | -173,678,000 | -165,614,000 | -149,499,000 | -94,015,000 | -167,504,000 | -127,489,000 | -119,939,000 | -124,567,000 | -102,487,000 | -78,638,000 | -54,532,000 | -69,249,000 |
| yoy | -23.51% | -30529.15% | 27.40% | 21.60% | 20.15% | -100.27% | 37.28% | 22.13% | 82.22% | -27.36% | -21.97% | -13.63% | -14.72% | 3.69% | 29.90% | 24.65% | -24.53% | 63.44% | 62.12% | 119.94% | 79.88% | ||||
| qoq | 28.65% | -53.82% | 17.88% | 9.23% | -51277.55% | -100.19% | 12.51% | 7.94% | 15.80% | -2.37% | 0.09% | 61.04% | -53.84% | 4.87% | 10.78% | 59.02% | -43.87% | 31.39% | 6.29% | -3.72% | 21.54% | 30.33% | 44.21% | -21.25% | |
| operating margin % | -3842.69% | -7018.67% | -8096.82% | 0.16% | -10167.11% | -3854.61% | -8903.05% | ||||||||||||||||||
| other income, net: | |||||||||||||||||||||||||
| interest income | 3,898,000 | 5,385,000 | 4,683,000 | 3,296,000 | 5,195,000 | 4,075,000 | 5,578,000 | 3,793,000 | 4,514,000 | 4,153,000 | 4,092,000 | 2,417,000 | 766,000 | 267,000 | 182,000 | 234,000 | 323,000 | 394,000 | 448,000 | 692,000 | 934,000 | 1,941,000 | 2,410,000 | 2,736,000 | 1,662,000 |
| interest expense | -37,637,000 | -42,141,000 | -29,821,000 | -23,061,000 | -22,937,000 | -23,471,000 | -20,268,000 | -20,306,000 | -20,594,000 | -20,121,000 | -19,990,000 | -19,825,000 | -20,279,000 | -20,344,000 | -15,134,000 | -11,067,000 | -10,839,000 | -9,738,000 | -10,962,000 | -10,929,000 | -10,754,000 | -4,010,000 | -3,040,000 | -2,113,000 | -1,941,000 |
| gain on deconsolidation of a subsidiary | 126,294,000 | ||||||||||||||||||||||||
| losses on extinguishments of debt | |||||||||||||||||||||||||
| net income from equity method investments | -20,189,000 | -15,556,000 | -16,695,000 | -6,563,000 | |||||||||||||||||||||
| other income | 6,548,000 | 8,231,000 | 1,624,000 | 1,797,000 | -632,000 | 9,483,000 | 21,778,000 | -5,283,000 | 1,476,000 | -601,000 | 4,560,000 | 6,331,000 | -10,816,000 | -7,575,000 | 28,284,000 | -684,000 | 2,457,000 | 5,766,000 | 2,978,000 | 9,000 | -1,827,000 | 474,000 | -1,170,000 | -26,000 | -7,000 |
| total other income | -47,380,000 | -65,236,000 | -40,209,000 | 27,496,000 | 99,995,000 | -36,503,000 | 7,088,000 | -21,796,000 | -14,604,000 | -16,569,000 | -11,338,000 | -11,077,000 | 77,617,000 | -27,652,000 | 13,332,000 | -11,517,000 | -8,059,000 | -3,578,000 | -7,536,000 | -10,228,000 | -11,647,000 | -1,595,000 | -5,513,000 | -6,132,000 | -5,016,000 |
| income before income taxes | -181,658,000 | ||||||||||||||||||||||||
| income tax expense | 2,100,000 | ||||||||||||||||||||||||
| net income | -183,758,000 | -169,608,000 | -267,389,000 | -164,254,000 | -75,544,000 | -36,160,000 | -170,328,000 | -179,488,000 | -160,703,000 | -142,732,000 | -140,570,000 | -140,193,000 | -2,559,000 | -201,330,000 | -152,282,000 | -161,016,000 | -102,074,000 | -171,082,000 | -135,025,000 | -130,167,000 | -136,214,000 | -104,082,000 | -84,151,000 | -60,664,000 | |
| yoy | 143.25% | 369.05% | 56.98% | -8.49% | -52.99% | -74.67% | 21.17% | 28.03% | 6179.91% | -29.11% | -7.69% | -12.93% | -97.49% | 17.68% | 12.78% | 23.70% | -25.06% | 64.37% | 60.46% | 114.57% | |||||
| qoq | 8.34% | -36.57% | 62.79% | 117.43% | 108.92% | -78.77% | -5.10% | 11.69% | 12.59% | 1.54% | 0.27% | 5378.43% | -98.73% | 32.21% | -5.42% | 57.74% | -40.34% | 26.70% | 3.73% | -4.44% | 30.87% | 23.68% | 38.72% | ||
| net income margin % | -4545.89% | -6012.23% | -3484.50% | -17.13% | -9760.92% | -4387.39% | -9792.99% | ||||||||||||||||||
| net income attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 1,855,000 | 2,186,000 | 2,339,000 | 2,214,000 | 2,088,000 | 944,000 | 2,180,000 | 2,489,000 | 2,576,000 | 2,979,000 | 2,854,000 | 4,933,000 | 5,105,000 | 5,081,000 | 5,726,000 | 8,003,000 | 15,044,000 | 14,308,000 | 15,180,000 | 12,232,000 | 10,693,000 | 684,000 | 8,370,000 | ||
| net income attributable to common stockholders of bridgebio | -181,903,000 | -167,422,000 | -265,050,000 | -162,040,000 | -73,456,000 | -35,216,000 | -168,148,000 | -176,999,000 | -157,899,000 | -140,156,000 | -137,591,000 | -137,339,000 | -9,856,000 | -196,397,000 | -147,177,000 | -155,935,000 | -96,348,000 | -163,079,000 | -119,981,000 | -115,859,000 | -121,034,000 | -91,850,000 | -73,458,000 | -59,980,000 | |
| net income per share | -0.95 | -0.88 | -1.42 | -0.86 | -0.39 | -0.2 | -0.96 | -1.08 | -0.98 | -0.92 | -0.92 | -0.93 | -0.07 | -1.35 | -1.02 | -1.06 | -0.66 | -1.18 | -1.01 | -0.98 | -1.03 | -0.78 | -0.62 | -0.51 | |
| weighted-average shares used for eps calculation | 190,517,215 | 190,145,253 | 186,075,873 | 188,510,372 | 187,586,680 | 178,705,310 | 162,791,511 | 163,308,632 | 160,535,435 | 152,645,635 | 147,473,076 | 147,937,817 | 146,684,804 | 145,882,149 | 144,356,619 | 146,662,756 | 146,754,299 | 138,627,729 | 117,995,457 | 118,168,063 | 117,012,062 | 117,803,438 | 105,099,089 | 117,071,188 | |
| cost of license and services revenue | 605,000 | ||||||||||||||||||||||||
| loss on extinguishment of debt | -21,155,000 | -26,590,000 | |||||||||||||||||||||||
| revenue | 5,882,000 | 2,732,000 | 2,168,000 | 211,120,000 | 1,745,000 | 4,091,000 | 1,641,000 | ||||||||||||||||||
| yoy | 237.08% | -33.22% | 32.11% | ||||||||||||||||||||||
| qoq | 115.30% | 26.01% | -98.97% | 11998.57% | -57.35% | 149.30% | |||||||||||||||||||
| cost of revenue | 2,084,000 | 598,000 | 598,000 | 598,000 | 598,000 | 598,000 | 599,000 | ||||||||||||||||||
| gross profit | 3,798,000 | 2,134,000 | 1,570,000 | 210,522,000 | 1,147,000 | 3,493,000 | 1,042,000 | ||||||||||||||||||
| yoy | 231.12% | -38.91% | 50.67% | ||||||||||||||||||||||
| qoq | 77.98% | 35.92% | -99.25% | 18254.14% | -67.16% | 235.22% | |||||||||||||||||||
| gross margin % | 64.57% | 78.11% | 72.42% | 99.72% | 65.73% | 85.38% | 63.50% | ||||||||||||||||||
| gain on deconsolidation of subsidiaries | 52,027,000 | ||||||||||||||||||||||||
| net income from equity method investment | -7,925,000 | ||||||||||||||||||||||||
| gain from sale of priority review voucher | 107,946,000 | ||||||||||||||||||||||||
| net income (income) attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 2,804,000 | -7,297,000 | |||||||||||||||||||||||
| revenue: | |||||||||||||||||||||||||
| product sales | 95,000 | 1,459,000 | 2,047,000 | 759,000 | 987,000 | ||||||||||||||||||||
| total revenue | 1,826,000 | 1,870,000 | 338,000 | 73,746,000 | 1,694,000 | 12,886,000 | 2,344,000 | 54,024,000 | |||||||||||||||||
| cost of license revenue and products sold | 651,000 | 647,000 | 739,000 | 700,000 | 1,348,000 | ||||||||||||||||||||
| license revenue | 235,000 | 10,839,000 | 1,585,000 | 53,037,000 | 462,000 | 122,000 | 8,127,000 | 13,819,000 | 26,741,000 | ||||||||||||||||
| cost of products sold | 1,172,000 | 1,454,000 | 109,000 | ||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||
| general and administrative | 45,407,000 | 37,437,000 | 36,016,000 | 37,969,000 | 34,262,000 | 34,972,000 | 23,495,000 | 16,918,000 | |||||||||||||||||
| total operating expenses | 167,966,000 | 127,611,000 | 128,066,000 | 124,567,000 | 102,487,000 | 92,457,000 | 81,273,000 | 69,249,000 | |||||||||||||||||
| cost of license revenue | 2,500,000 | ||||||||||||||||||||||||
| share in net income of an equity method investment | |||||||||||||||||||||||||
| income from ml bio asset acquisition | -416,000 | ||||||||||||||||||||||||
| income from pellepharm | -4,036,000 | -6,589,000 | -4,956,000 | ||||||||||||||||||||||
| leo call option income | -253,000 | 276,000 | 226,000 | ||||||||||||||||||||||
| net income and comprehensive loss | -74,265,000 | ||||||||||||||||||||||||
| net income and comprehensive loss attributable to bridgebio | -65,895,000 | ||||||||||||||||||||||||
| cumulative returns on redeemable convertible preferred units | |||||||||||||||||||||||||
| net income attributable to redeemable founder units and redeemable common units | -65,895,000 | ||||||||||||||||||||||||
| net income per unit attributable to redeemable founder unitholders and redeemable common unitholders, basic and diluted | -3,460 | ||||||||||||||||||||||||
| total weighted-average redeemable founder units and redeemable common units used in computing net income per unit, basic and diluted | 19,033,838,000 |
We provide you with 20 years income statements for BridgeBio Pharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BridgeBio Pharma stock. Explore the full financial landscape of BridgeBio Pharma stock with our expertly curated income statements.
The information provided in this report about BridgeBio Pharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.